Products Categories
CAS No.: | 135159-51-2 |
---|---|
Name: | Sarpogrelate hydrochloride |
Article Data: | 5 |
Molecular Structure: | |
Formula: | C24H32ClNO6 |
Molecular Weight: | 465.974 |
Synonyms: | Butanedioicacid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl]ester, hydrochloride (9CI);Anplag;MCI 9042;Butanedioicacid,1-[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl]ester, hydrochloride (1:1); |
EINECS: | 663-199-9 |
Melting Point: | 145-148°C |
Boiling Point: | 585.9 °C at 760 mmHg |
Flash Point: | 308.1 °C |
Appearance: | colorless liquid |
Hazard Symbols: | Xn,N |
Risk Codes: | 22-50/53 |
Safety: | 60-61 |
PSA: | 85.30000 |
LogP: | 3.99940 |
What can I do for you?
Get Best Price
Structure of Sarpogrelate hydrochloride (CAS NO.135159-51-2):
IUPAC Name: 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid hydrochloride
Empirical Formula: C24H32ClNO6
Molecular Weight: 465.967
Flash Point: 308.1 °C
Enthalpy of Vaporization: 92.05 kJ/mol
Boiling Point: 585.9 °C at 760 mmHg
Vapour Pressure: 1.43E-14 mmHg at 25°C
Synonyms of Sarpogrelate hydrochloride (CAS NO.135159-51-2): Anplag ; MCI-9042 ; Sarpogrelate HCl ; Butanedioicacid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl]ester, hydrochloride (9CI) .
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | oral | > 3gm/kg (3000mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl, |
mouse | LD50 | intraperitoneal | 65mg/kg (65mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: PERITONITIS | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl, |
mouse | LD50 | intravenous | > 45mg/kg (45mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl, |
mouse | LD50 | oral | 2550mg/kg (2550mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl, |
rat | LD50 | intraperitoneal | 108mg/kg (108mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: PERITONITIS | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl, |
rat | LD50 | intravenous | > 45mg/kg (45mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl, |
rat | LD50 | oral | 4400mg/kg (4400mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl, |